The total return over the past 12 months is -2.62% vs. +16.94% for the S&P 500. So far it's up -16.21% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (2.62%) | +42.05% | +11.75% | +16.60% | N/A | N/A |
| Total Return CAGR | (2.62%) | +42.05% | +11.75% | +16.60% | N/A | N/A |
| Revenue CAGR | (42.84%) | +7.20% | +16.41% | +33.28% | N/A | N/A |
| Net Income CAGR | (106.10%) | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | (106.11%) | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | (148.83%) | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | (104.33%) | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
PTC Therapeutics, Inc. (PTCT)
| Year | Start price | End price | PTCT Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $75.96 | $63.65 | (16.21%) | +14.51% | (30.72%) |
| 2025 | $45.14 | $75.96 | +68.28% | +17.72% | +50.56% |
| 2024 | $27.56 | $45.14 | +63.79% | +24.89% | +38.90% |
| 2023 | $38.17 | $27.56 | (27.80%) | +26.19% | (53.99%) |
| 2022 | $39.83 | $38.17 | (4.17%) | (18.17%) | +14.00% |
| 2021 | $61.03 | $39.83 | (34.74%) | +28.74% | (63.48%) |
| 2020 | $48.03 | $61.03 | +27.07% | +18.37% | +8.70% |
| 2019 | $34.32 | $48.03 | +39.95% | +31.22% | +8.73% |
| 2018 | $16.68 | $34.32 | +105.76% | (4.56%) | +110.32% |
| 2017 | $10.91 | $16.68 | +52.89% | +21.70% | +31.19% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
